REVIEW

The immunology of Zika Virus [version 1; peer review: 2 approved]

Abigail Culshaw¹, Juthathip Mongkolsapaya^{1,2}, Gavin Screaton³

¹Department of Medicine, Imperial College London, Hammersmith Campus, Du Cane Road, London, W12 0NN, UK

²Dengue Hemorrhagic Fever Research Unit, Office for Research and Development, Siriraj Hospital, Faculty of Medicine, Mahidol University, Bangkok, Thailand

³Medical Sciences Division, University of Oxford, Level 3, John Radcliffe Hospital, Oxford, OX3 9DU, UK

V1 First published: 19 Feb 2018, 7(F1000 Faculty Rev):203
<https://doi.org/10.12688/f1000research.12271.1>

Latest published: 19 Feb 2018, 7(F1000 Faculty Rev):203
<https://doi.org/10.12688/f1000research.12271.1>

Abstract

Zika virus (ZIKV) was initially thought to cause only mild, self-limiting symptoms. However, recent outbreaks have been associated with the autoimmune disease Guillain-Barré syndrome and causally linked to a congenital malformation known as microcephaly. This has led to an urgent need for a safe and effective vaccine. A comprehensive understanding of the immunology of ZIKV infection is required to aid in the design of such a vaccine. Whilst details of both innate and adaptive immune responses to ZIKV are emerging, further research is needed. As immunopathogenesis has been implicated in poor outcomes following infection with the related dengue virus, identification of cross-reactive immune responses between flaviviruses and the impact they may have on disease progression is also of high importance.

Keywords

Zika virus, dengue virus, innate immunity, antibodies, T cells, immunopathogenesis, vaccine

Open Peer Review

Approval Status

	1	2
version 1
19 Feb 2018		

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

1. **Mehul Suthar**, Emory University, Atlanta, USA
2. **Pei-Yong Shi**, University of Texas Medical Branch, Galveston, USA

Any comments on the article can be found at the end of the article.

Corresponding author: Gavin Screaton (g.screaton@imperial.ac.uk)

Author roles: Culshaw A: Writing – Original Draft Preparation, Writing – Review & Editing; Mongkolsapaya J: Writing – Review & Editing; Screaton G: Funding Acquisition, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: This work was supported by the Newton Fund Medical Research Council UK and the Wellcome Trust (078121/Z/05/Z).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2018 Culshaw A *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Culshaw A, Mongkolsapaya J and Screaton G. **The immunology of Zika Virus [version 1; peer review: 2 approved]** F1000Research 2018, 7(F1000 Faculty Rev):203 <https://doi.org/10.12688/f1000research.12271.1>

First published: 19 Feb 2018, 7(F1000 Faculty Rev):203 <https://doi.org/10.12688/f1000research.12271.1>

Introduction

Zika virus (ZIKV) was first isolated from a febrile non-human primate in the Zika Forest of Uganda in 1947¹ (Figure 1). Very few cases of human infection were reported in the subsequent decades² until 2007, when an outbreak occurred on the island of Yap in the Federated States of Micronesia³. In 2013, some 30,000 cases of ZIKV infection were recorded in French Polynesia⁴. Up to this point, the virus was believed to cause only a mild, self-limiting febrile illness. However, ZIKV transmission in French Polynesia was associated with the development of the neurological autoimmune disease Guillain-Barré syndrome (GBS)⁵.

After 2013, ZIKV emerged in South America, first appearing in Chile⁶ and then going on to cause a large-scale outbreak in Brazil. It is estimated that by the end of 2015 between 440,000 and 1.3 million people had been infected in Brazil⁷. This increase in ZIKV prevalence was coincident with a rise in the occurrence of a congenital malformation known as microcephaly⁸. This birth defect results in a reduction in head size, causing several complications, including developmental delay.

Owing to the severe nature of complications arising from ZIKV transmission, the development of a safe and effective vaccine has become a priority for the research community. An extensive understanding of the immunology of ZIKV infection is vital to inform the design of such a vaccine. Owing to the relatedness of ZIKV to other flaviviruses that co-circulate in endemic regions, it is also of importance to understand how cross-reactive immune responses might impact on the outcome of ZIKV infection.

Zika virus

ZIKV is a member of the flavivirus family, which includes other important human pathogens such as dengue virus (DENV), yellow fever virus (YFV), West Nile virus (WNV), Japanese encephalitis virus, and tick-borne encephalitis virus. ZIKV is an arthropod-borne virus that is transmitted via the bite of infected *aedes* mosquitoes⁹. Seemingly unique amongst flaviviruses,

ZIKV can also be transmitted by the aforementioned perinatal route as well as via sexual contact^{10,11}. Furthermore, the sexual transmission of ZIKV can potentially occur long after acute infection, as virus has been detected in semen more than 6 months after symptomatic disease¹². ZIKV has also been shown to cause damage to the testes and affect fertility in a mouse model of infection¹³.

As with other flaviviruses, ZIKV has a single-stranded positive-sense RNA genome that is translated into a single polyprotein. This polyprotein is cleaved into three structural proteins—capsid, pre-membrane (PrM), and envelope (E)—and seven non-structural (NS) proteins: NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5. The surface structure of the mature ZIKV virion is composed of 90 anti-parallel E dimers arranged in a herringbone formation¹⁴. This is similar to the structure of both DENV and WNV.

Immune responses to Zika virus

The innate immune response

The interferon (IFN) response plays a critical role in the control of flaviviruses, as shown by the increased susceptibility of mice lacking components of the IFN pathway to flaviviral infection^{15,16} and the numerous mechanisms employed by flaviviruses to counteract this control^{17,18}.

Several *in vitro* studies using both primary human cells and human-derived cell lines have been undertaken to assess the IFN response to ZIKV infection. Dependent on the cell type used, ZIKV infection resulted in the production of type I (α , β), type II (γ), and type III (λ) IFN as well as the activation of several IFN-stimulated genes (ISGs)^{19–22}.

Investigations to determine the mechanisms employed by ZIKV to dampen the IFN response have also been carried out. The ZIKV NS5 protein has been shown to degrade STAT2, a signalling molecule involved in the type I IFN pathway²³. This limits type I IFN signalling and allows increased viral replication. This appears to be a species-specific interaction, as ZIKV NS5 is

Figure 1. Timeline of the spread of Zika virus (ZIKV). Following its isolation in Uganda in 1947, ZIKV caused only sporadic incidences of human infection until an outbreak on the island of Yap in 2007. Since then, the virus has spread through the South Pacific to South America, resulting in large-scale transmission that is associated with severe complications such as Guillain-Barré syndrome and microcephaly.

unable to degrade murine STAT2, contributing to the inefficient replication of ZIKV seen in immunocompetent mice and the increased susceptibility of mice lacking components of the type I IFN signalling pathway to infection with ZIKV.

However, it should be noted that this study relies on the over-expression of NS5. Furthermore, another investigation using infected human dendritic cells suggests another mechanism of ZIKV-mediated IFN inhibition. That study found ZIKV infection to result in the antagonism of STAT1 and STAT2 phosphorylation²⁴. As yet, it is unclear which mechanism might occur first or whether both take place during natural infection.

The antibody response

The structural proteins E and PrM along with the secreted protein NS1 represent the major targets for flavivirus-specific antibodies^{25,26}. Initial studies show that the ZIKV-specific antibody response conforms to this pattern²⁷, although additional comprehensive mapping experiments would be beneficial.

Studies have shown ZIKV-specific antibodies to be crucial for viral control in mouse models of infection. A DNA vaccine comprising ZIKV PrM and E protected mice from viral challenge, resulting in an absence of detectable viremia. This protection was mediated by E-specific antibodies, as demonstrated by passive transfer experiments²⁸. This same vaccine was also found to be protective in rhesus macaques²⁹.

Several human monoclonal antibodies capable of neutralising ZIKV both *in vitro* and *in vivo* have been isolated. These include antibodies to the quaternary E dimer epitope, which cross-react between ZIKV and DENV^{30–32}. Antibodies recognising domain III of ZIKV E protein, which reduce disease symptoms and mortality in ZIKV-infected mice, have also been identified³³. In addition, two antibodies, which recognise epitopes spanning multiple domains of the ZIKV E protein, were found to protect mice in a post-exposure model³⁴.

The T-cell response

The immunodominant DENV-specific CD8⁺ T-cell response is directed toward the NS proteins NS3 and NS5, although epitopes have been identified across the genome. Further work is required to determine which ZIKV proteins are the major targets of the T-cell response in humans.

One study in IFN receptor (IFNR) type I-deficient mice found ZIKV-specific CD8⁺ T cells to predominantly target the PrM, E, and NS5 proteins. It was demonstrated that such cells have a protective role during infection, as adoptive transfer led to a reduction in virus load following challenge³⁵. In an IFNR type I-deficient HLA transgenic mouse model, ZIKV-specific T cells were found to recognise epitopes across all 10 proteins. These T cells were also shown to be protective during ZIKV infection, as immunisation with peptide epitopes resulted in a reduction in virus load following challenge³⁶. This reduction was abrogated following the depletion of CD8⁺ T cells.

Depletion of T cells resulted in ZIKV-induced weight loss in both wild-type and IFN-deficient mice. This study also found CD4⁺ and CD8⁺ T-cell responses toward ZIKV to be dampened during pregnancy³⁷. If this is the case for human ZIKV infections, it could have implications for the development of microcephaly.

Caution is required when extrapolating data from mouse studies to be applied to humans. With the exception of the HLA transgenic model, the mice used in the experiments described above display distinct major histocompatibility complex molecules to humans. This will lead to the recognition of different T-cell epitopes. In addition, many of these studies were carried out in mice lacking components of the IFN pathway, which plays an important role in the generation of a fully functional T-cell response.

Studies investigating T-cell responses during human ZIKV infection are sparse at present. CD4⁺ T cells that proliferate in response to stimulation with E and NS1 have been identified in humans who had experienced a recent ZIKV infection²⁷, and *in silico* analysis has been used to predict ZIKV T-cell epitopes³⁸. Therefore, substantial further research is required to confirm a protective role for T cells during ZIKV infection in humans.

Flavivirus cross-reactive immune responses: immunopathogenesis or protection?

ZIKV transmission is taking place in areas where other flaviviruses are circulating. Therefore, ZIKV infections will be occurring in populations with previous flavivirus immunity. It will be of importance to understand how such immunity will impact on the outcome of ZIKV infection. Particular focus has been given to cross-reactivity between DENV and ZIKV, as the E proteins are closely related³⁰. Moreover, immunopathogenesis has been implicated in contributing to the severe symptoms of DENV infection.

DENV co-circulates as four closely related serotypes, and sequential infections are common. Individuals experiencing a secondary or subsequent infection are more likely to develop serious complications^{39,40}, suggesting a role for virus-specific immunity in pathogenesis. The mechanism for antibody involvement is well defined. Subneutralising levels of DENV-specific antibodies can lead to opsonisation of virus particles and increased entry into Fc receptor-bearing cells⁴¹. Such cells are a major site of DENV replication, thus leading to increased viral replication in a phenomenon known as antibody-dependent enhancement (ADE).

The role of serotype cross-reactive T cells in DENV pathogenesis is more contentious. CD8⁺ T cells that preferentially recognise epitopes derived from the primary infecting serotype have been identified⁴². The expansion of cells generated during a primary infection but displaying a low avidity for the current infecting serotype may result in delayed viral clearance and higher viral loads. However, studies in both humans and mice have suggested a protective role for serotype cross-reactive T cells^{43–46}.

The role that immunopathogenesis plays in the outcome of DENV infection along with the genetic similarities and co-circulation of both ZIKV and DENV lead to some important questions that need addressing. Can DENV-specific immune responses affect the outcome of ZIKV infection and vice versa? How might pre-existing flaviviral immunity impact on the maternal-fetal transmission of ZIKV? What implications might the answers to these questions have for vaccine design?

Dengue virus cross-reactive antibodies

Several studies have identified antibodies that are cross-reactive between DENV and ZIKV^{27,30–33,47,48}. Furthermore, it has been demonstrated that DENV-specific antibodies are able to enhance infection of Fc receptor-bearing cells with ZIKV *in vitro*^{31,47,49,50}. Adoptive transfer of DENV convalescent plasma enhanced pathogenesis in a mouse model of ZIKV infection⁴⁹, suggesting a role for ADE *in vivo*. Conversely, pre-existing DENV immunity did not result in more severe ZIKV disease in rhesus macaques⁵¹.

However, both of these studies have limitations that should be considered when interpreting their data. The adoptive transfer experiments used immunocompromised mice, and the macaques displayed no symptoms of disease following infection. In addition, differences in experimental design may account for the disparate findings seen. Whilst antibodies alone were transferred into the mice two hours prior to infection, the macaques were infected with DENV two and a half years before ZIKV exposure. This may impact on the nature of the DENV-specific antibody response present. Moreover, in the macaques, other components of a DENV-specific immune response would be present alongside the antibodies, potentially affecting the outcome of ZIKV infection.

Therefore, whether or not the mechanism of ADE is at play during natural infection requires further research, and in particular the development of serological reagents to distinguish previous ZIKV and DENV infections is essential to probe epidemiological cohorts. DENV-specific antibodies with the ability to neutralise ZIKV infection *in vitro* have been identified^{27,30–32}, and monoclonal antibodies isolated from patients with dengue have been found to protect mice during ZIKV challenge^{32,33}.

Of importance to this mechanism is the question of which cell types provide the major site of replication for ZIKV. If ZIKV predominantly replicates in non-Fc receptor-bearing cells, then DENV-specific antibodies are unlikely to have a major impact on pathogenesis. There is mounting evidence to suggest that the tissue tropism of ZIKV is distinct from that of DENV⁵².

It may be that certain serotypes of DENV differ in their ability to generate a pathogenic or a beneficial antibody response. It may also be of importance how many previous DENV infections an individual has been exposed to. One previous DENV infection may enhance Zika disease, whereas two or more may turn out to be protective, as is the case for sequential DENV infections⁵³. As is also the case for DENV, the time gap between infections could be crucial⁵⁴.

Dengue virus cross-reactive T cells

In addition to antibodies, DENV and ZIKV cross-reactive T cells have been identified. The study described above involving humanised mice identified T cells specific for several epitopes that were either ZIKV specific or cross-reactive between ZIKV and DENV. Both types of peptide epitope were used to immunise mice prior to ZIKV challenge and were found to be protective³⁶. Although the peptides used in this study were divided into two groups based on their cross-reactivity to DENV, all were exactly sequence-matched to the strain of ZIKV used to challenge the mice. To develop these findings further, it would be useful to ascertain whether T cells specific for DENV that are partially cross-reactive toward ZIKV are also protective.

In another mouse model of infection, CD8⁺ T cells from ZIKV-infected wild-type mice were found to protect type I IFNR knockout mice during both ZIKV and DENV infection⁵⁵. It has also been shown that adoptive transfer of DENV-specific CD8⁺ T cells can confer protection during ZIKV infection of type I IFNR knockout mice⁵⁶.

The previously mentioned study that found memory T cells specific for NS1 and E following ZIKV infection of humans demonstrated these cells to be poorly cross-reactive with DENV, even in those individuals who had experienced a previous DENV infection²⁷. In contrast, *in silico* analysis has identified T-cell reactivity conserved across several flaviviruses, including ZIKV predominantly found in the NS3 and NS5 proteins³⁸. In addition, a study of a human cohort revealed previous DENV exposure to affect the magnitude, timing, and quality of the ZIKV-specific T-cell response⁵⁷. Substantial further research is required to establish the role that T cells play during ZIKV infections and whether or not DENV cross-reactive T cells can contribute to pathogenesis or protection.

Vaccine development

Several vaccine strategies have been found to be protective in either mouse or non-human primate models of ZIKV infection. These include DNA vaccines^{28,29,58,59}, RNA vaccines^{60,61}, live attenuated virus⁶², inactivated virus^{28,29,63}, and virus-like particles⁶⁴. Vaccines have also been found to block the transmission of ZIKV to the foetus of pregnant mice⁶⁵. Some of these vaccines are currently in the early stages of clinical trials in humans (Table 1).

Most of these vaccines are aimed at generating antibodies specific for the ZIKV virion. Analysis of other flaviviral vaccines has shown levels of E-specific antibodies to correlate with protection in both animals and humans⁶⁶. However, it has been suggested that the lack of efficacy of the recently licensed DENV vaccine may be due in part to its inability to generate an effective DENV-specific T-cell response, as the NS proteins contained within it are derived from YFV⁶⁷. Therefore, developing a ZIKV vaccine that aims to induce both an antibody and a T-cell response may prove beneficial.

A ZIKV vaccine may need to be used in pregnant women or immunocompromised individuals, which could raise safety concerns with live attenuated vaccines because of the risk of

Table 1. Current Zika virus vaccine trials.

Phase	Name	Strain	Target	Strategy	Sponsor	References
I	VRC-ZKADNA085-00-VP	H/PF/2013	PrM-E	DNA vaccine	National Institutes of Health	28,29
	VRC-ZKADNA090-00-VP	H/PF/2013	PrM-E	DNA vaccine	National Institutes of Health	
	GLS-5700	Consensus	PrM-E	DNA vaccine	GeneOne	59
	ZPIV	PRVABC59	Whole virion	Inactivated virus	Walter Reed Army Institute of Research/National Institute of Allergy and Infectious Diseases	28,29
	MV-ZIKA		E	Viral vector	Themis	
I/II	mRNA-1325	Micronesia 2007	PrM-E	mRNA vaccine	Moderna Therapeutics	61

E, envelope; PrM, pre-membrane.

reversion. Such vaccines are, however, cost-effective to produce and often result in durable immunity, even after one dose. Other vaccine strategies present viable alternatives to live attenuated vaccines. DNA plasmid vaccines are easy to produce and are physically and genetically stable, and inactivated vaccines are already in use for other flaviviruses. However, both of these vaccine strategies may turn out to be less immunogenic as compared with a live vaccine⁶⁶.

Another consideration during the development of a ZIKV vaccine is that it may be difficult to determine the threshold of protection to prevent foetal transmission and microcephaly. Complete sterilising immunity may be required to prevent infection of the foetus, and assessing whether this has been achieved during a vaccine trial in which the endpoint is prevention of symptomatic infection will be challenging.

Monitoring should be undertaken to ensure that vaccination does not lead to increased susceptibility to severe outcomes following infection with other flaviviruses such as DENV. The mechanism of GBS following ZIKV infection, which occurs in an estimated 1 in every 4,000 cases⁵, is not yet clear. However, auto-reactive antibodies have been shown to be present during GBS triggered by other pathogens⁶⁸. It will therefore be important to monitor vaccinees for symptoms of GBS.

Conclusions

Since the association between ZIKV and severe complications such as GBS and microcephaly emerged, much research has been carried out, resulting in a substantial increase in our knowledge of the immunology of ZIKV infection. Proteins and, in some instances, epitopes targeted by antibodies and T cells during human ZIKV infection have been determined. Following the development of mouse models, protective antibody and T-cell responses

have been identified. Several vaccine strategies have been tested in animal models, and early clinical trials have begun in humans. Caution and further insight are required in order to ensure that such vaccines will have no detrimental effects and will provide long-term protection.

Immunopathogenesis has been implicated as a contributing factor to DENV disease. Sequential infections with DENV and ZIKV are likely to occur because of the co-circulation of both viruses in endemic areas. DENV/ZIKV cross-reactive immune responses have already been identified, which is perhaps unsurprising given the sequence homology between the two viruses. A DENV vaccine is currently licensed for use in several countries experiencing ZIKV outbreaks. Gaining a comprehensive understanding of the effect that DENV immunity has during ZIKV infection and vice versa is crucial for the design of safe vaccine strategies.

Abbreviations

ADE, antibody-dependent enhancement; DENV, dengue virus; E, envelope; GBS, Guillain-Barré syndrome; IFN, interferon; IFNR, interferon receptor; NS, non-structural; PrM, pre-membrane; WNV, West Nile virus; YFV, yellow fever virus; ZIKV, Zika virus.

Competing interests

The authors declare that they have no competing interests.

Grant information

This work was supported by the Newton Fund Medical Research Council UK and the Wellcome Trust (078121/Z/05/Z).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

1. Dick GW, Kitchen SF, Haddock AJ: **Zika virus. I. Isolations and serological specificity.** *Trans R Soc Trop Med Hyg.* 1952; 46(5): 509–20.
[PubMed Abstract](#) | [Publisher Full Text](#)
2. Faye O, Freire CC, Iamarino A, *et al.*: **Molecular evolution of Zika virus during its emergence in the 20th century.** *PLoS Negl Trop Dis.* 2014; 8(1): e2636.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. Duffy MR, Chen TH, Hancock WT, *et al.*: **Zika virus outbreak on Yap Island, Federated States of Micronesia.** *N Engl J Med.* 2009; 360(24): 2536–43.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
4. Musso D, Nilles EJ, Cao-Lormeau VM: **Rapid spread of emerging Zika virus in the Pacific area.** *Clin Microbiol Infect.* 2014; 20(10): O595–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
5. Cao-Lormeau VM, Blake A, Mons S, *et al.*: **Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study.** *Lancet.* 2016; 387(10027): 1531–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
6. Tognarelli J, Ulloa S, Villagra E, *et al.*: **A report on the outbreak of Zika virus on Easter Island, South Pacific, 2014.** *Arch Virol.* 2016; 161(3): 665–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Hennessey M, Fischer M, Staples JE: **Zika Virus Spreads to New Areas - Region of the Americas, May 2015-January 2016.** *MMWR Morb Mortal Wkly Rep.* 2016; 65(3): 55–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
8. Rapid risk assessment: **Zika virus epidemic in the Americas: potential association with microcephaly and Guillain-Barré syndrome.** Stockholm: European Centre for Disease Prevention and Control, December 10, 2015. [cited] [Reference Source](#)
9. Musso D, Gubler DJ: **Zika Virus.** *Clin Microbiol Rev.* 2016; 29(3): 487–524.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Musso D, Roche C, Robin E, *et al.*: **Potential sexual transmission of Zika virus.** *Emerg Infect Dis.* 2015; 21(2): 359–61.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
11. McCarthy M: **Zika virus was transmitted by sexual contact in Texas, health officials report.** *BMJ.* 2016; 352: i720.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Nicastri E, Castilletti C, Luzzati G, *et al.*: **Persistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016.** *Euro Surveill.* 2016; 21(32): 30314.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
13. Ma W, Li S, Ma S, *et al.*: **Zika Virus Causes Testis Damage and Leads to Male Infertility in Mice.** *Cell.* 2016; 167(6): 1511–1524.e10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
14. Kostyuchenko VA, Lim EX, Zhang S, *et al.*: **Structure of the thermally stable Zika virus.** *Nature.* 2016; 533(7603): 425–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
15. Lazear HM, Govero J, Smith AM, *et al.*: **A Mouse Model of Zika Virus Pathogenesis.** *Cell Host Microbe.* 2016; 19(5): 720–30.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
16. Shrestha S, Kyle JL, Snider HM, *et al.*: **Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical.** *J Virol.* 2004; 78(6): 2701–10.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Quicke KM, Suthar MS: **The innate immune playbook for restricting West Nile virus infection.** *Viruses.* 2013; 5(11): 2643–58.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Morrison J, Laurent-Rolle M, Maestre AM, *et al.*: **Dengue virus co-opts UBR4 to degrade STAT2 and antagonize type I interferon signaling.** *PLoS Pathog.* 2013; 9(3): e1003265.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
19. Hamel R, Dejarnac O, Wicht S, *et al.*: **Biology of Zika Virus Infection in Human Skin Cells.** *J Virol.* 2015; 89(17): 8880–96.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Bayer A, Lennemann NJ, Ouyang Y, *et al.*: **Type III Interferons Produced by Human Placental Trophoblasts Confer Protection against Zika Virus Infection.** *Cell Host Microbe.* 2016; 19(5): 705–12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Quicke KM, Bowen JR, Johnson EL, *et al.*: **Zika Virus Infects Human Placental Macrophages.** *Cell Host Microbe.* 2016; 20(1): 83–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
22. Chaudhary V, Yuen KS, Chan JF, *et al.*: **Selective Activation of Type II Interferon Signaling by Zika Virus NS5 Protein.** *J Virol.* 2017; 91(14): pii: e00163-17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
23. Grant A, Ponia SS, Tripathi S, *et al.*: **Zika Virus Targets Human STAT2 to Inhibit Type I Interferon Signaling.** *Cell Host Microbe.* 2016; 19(6): 882–90.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
24. Bowen JR, Quicke KM, Maddur MS, *et al.*: **Zika Virus Antagonizes Type I Interferon Responses during Infection of Human Dendritic Cells.** *PLoS Pathog.* 2017; 13(2): e1006164.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
25. Heinz FX, Stiasny K: **Flaviviruses and their antigenic structure.** *J Clin Virol.* 2012; 55(4): 289–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Muller DA, Young PR: **The flavivirus NS1 protein: molecular and structural biology, immunology, role in pathogenesis and application as a diagnostic biomarker.** *Antiviral Res.* 2013; 98(2): 192–208.
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Stettler K, Beltramelio M, Espinosa DA, *et al.*: **Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection.** *Science.* 2016; 353(6301): 823–6.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
28. Larocca RA, Abbink P, Peron JP, *et al.*: **Vaccine protection against Zika virus from Brazil.** *Nature.* 2016; 536(7617): 474–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
29. Abbink P, Larocca RA, De La Barrera RA, *et al.*: **Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys.** *Science.* 2016; 353(6304): 1129–32.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
30. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, *et al.*: **Structural basis of potent Zika-dengue virus antibody cross-neutralization.** *Nature.* 2016; 536(7614): 48–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
31. Dejnirattisai W, Supasa P, Wongwiwat W, *et al.*: **Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with Zika virus.** *Nat Immunol.* 2016; 17(9): 1102–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
32. Swanstrom JA, Plante JA, Plante KS, *et al.*: **Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus.** *MBio.* 2016; 7(4): pii: e01123-16.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
33. Robbiani DF, Bozzacco L, Keeffe JR, *et al.*: **Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico.** *Cell.* 2017; 169(4): 597–609.e11.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
34. Wang Q, Yang H, Liu X, *et al.*: **Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus.** *Sci Transl Med.* 2016; 8(369): 369ra179.
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Elong Ngono A, Vizcarra EA, Tang WW, *et al.*: **Mapping and Role of the CD8⁺ T Cell Response During Primary Zika Virus Infection in Mice.** *Cell Host Microbe.* 2017; 21(1): 35–46.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
36. Wen J, Tang WW, Sheets N, *et al.*: **Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8⁺ T cells.** *Nat Microbiol.* 2017; 2: 17036.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
37. Winkler CW, Myers LM, Woods TA, *et al.*: **Adaptive Immune Responses to Zika Virus Are Important for Controlling Virus Infection and Preventing Infection in Brain and Testes.** *J Immunol.* 2017; 198(9): 3526–35.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
38. Xu X, Vaughan K, Weiskopf D, *et al.*: **Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species.** *PLoS Curr.* 2016; 8: pii: ecurrents.outbreaks.9aa2e1fb61b0f632f58a098773008c4b.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
39. Sangkawibha N, Rojanasuphot S, Ahandrik S, *et al.*: **Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak.** *Am J Epidemiol.* 1984; 120(5): 653–69.
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Guzmán MG, Kouri G, Valdes L, *et al.*: **Epidemiologic studies on Dengue in Santiago de Cuba, 1997.** *Am J Epidemiol.* 2000; 152(9): 793–9; discussion 804.
[PubMed Abstract](#) | [Publisher Full Text](#)
41. Halstead SB, O'Rourke EJ: **Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody.** *J Exp Med.* 1977; 146(1): 201–17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
42. Mongkolsapaya J, Dejnirattisai W, Xu XN, *et al.*: **Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.** *Nat Med.* 2003; 9(7): 921–7.
[PubMed Abstract](#) | [Publisher Full Text](#)
43. Weiskopf D, Angelo MA, de Azeredo EL, *et al.*: **Comprehensive analysis of**

- dengue virus-specific responses supports an HLA-linked protective role for CD8⁺ T cells. *Proc Natl Acad Sci U S A*. 2013; 110(22): E2046–53.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
44. Zellweger RM, Miller R, Eddy WE, *et al.*: Role of humoral versus cellular responses induced by a protective dengue vaccine candidate. *PLoS Pathog*. 2013; 9(10): e1003723.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. **F** Zellweger RM, Tang WW, Eddy WE, *et al.*: CD8⁺ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice. *J Virol*. 2015; 89(12): 6494–505.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 46. Yauch LE, Zellweger RM, Kotturi MF, *et al.*: A protective role for dengue virus-specific CD8⁺ T cells. *J Immunol*. 2009; 182(8): 4865–73.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Priyamvada L, Quicke KM, Hudson WH, *et al.*: Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. *Proc Natl Acad Sci U S A*. 2016; 113(38): 7852–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 48. **F** Sapparapu G, Fernandez E, Kose N, *et al.*: Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. *Nature*. 2016; 540(7633): 443–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 49. **F** Bardina SV, Bunduc P, Tripathi S, *et al.*: Enhancement of Zika virus pathogenesis by preexisting ant flavivirus immunity. *Science*. 2017; 356(6334): 175–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 50. Paul LM, Carlin ER, Jenkins MM, *et al.*: Dengue virus antibodies enhance Zika virus infection. *Clin Transl Immunology*. 2016; 5(12): e117.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 51. **F** Pantoja P, Pérez-Guzmán EX, Rodríguez IV, *et al.*: Zika virus pathogenesis in rhesus macaques is unaffected by pre-existing immunity to dengue virus. *Nat Commun*. 2017; 8: 15674.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 52. Miner JJ, Diamond MS: Zika Virus Pathogenesis and Tissue Tropism. *Cell Host Microbe*. 2017; 21(2): 134–42.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 53. **F** Gibbons RV, Kalanaraoj S, Jarman RG, *et al.*: Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. *Am J Trop Med Hyg*. 2007; 77(5): 910–3.
[PubMed Abstract](#) | [F1000 Recommendation](#)
 54. **F** Anderson KB, Gibbons RV, Cummings DA, *et al.*: A shorter time interval between first and second dengue infections is associated with protection from clinical illness in a school-based cohort in Thailand. *J Infect Dis*. 2014; 209(3): 360–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 55. Huang H, Li S, Zhang Y, *et al.*: CD8⁺ T Cell Immune Response in Immunocompetent Mice during Zika Virus Infection. *J Virol*. 2017; 91(22): pii: e00900-17.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 56. **F** Wen J, Elong Ngono A, Regla-Nava JA, *et al.*: Dengue virus-reactive CD8⁺ T cells mediate cross-protection against subsequent Zika virus challenge. *Nat Commun*. 2017; 8(1): 1459.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 57. Grifoni A, Pham J, Sidney J, *et al.*: Prior Dengue virus exposure shapes T cell immunity to Zika virus in humans. *J Virol*. 2017; pii: JVI.01469-17
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 58. Dowd KA, Ko SY, Morabito KM, *et al.*: Rapid development of a DNA vaccine for Zika virus. *Science*. 2016; 354(6309): 237–40.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 59. Muthumani K, Griffin BD, Agarwal S, *et al.*: In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEV DNA vaccine. *NPJ Vaccines*. 2016; 1: 16021.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 60. Chahal JS, Fang T, Woodham AW, *et al.*: An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8⁺ T cell responses in a mouse model. *Sci Rep*. 2017; 7(1): 252.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 61. **F** Richner JM, Himansu S, Dowd KA, *et al.*: Modified mRNA Vaccines Protect against Zika Virus Infection. *Cell*. 2017; 169(1): 176.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 62. **F** Shan C, Muruato AE, Nunes BTD, *et al.*: A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. *Nat Med*. 2017; 23(6): 763–7.
[PubMed Abstract](#) | [Publisher Full Text](#) | [F1000 Recommendation](#)
 63. Sumathy K, Kulkarni B, Gondu RK, *et al.*: Protective efficacy of Zika vaccine in AG129 mouse model. *Sci Rep*. 2017; 7: 46375.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 64. Boigard H, Alimova A, Martin GR, *et al.*: Zika virus-like particle (VLP) based vaccine. *PLoS Negl Trop Dis*. 2017; 11(5): e0005608.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 65. **F** Richner JM, Jagger BW, Shan C, *et al.*: Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease. *Cell*. 2017; 170(2): 273–283.e12.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#) | [F1000 Recommendation](#)
 66. Diamond MS, Coyne CB: Vaccines in 2017: Closing in on a Zika virus vaccine. *Nat Rev Immunol*. 2018; 18(2): 89–90.
[PubMed Abstract](#) | [Publisher Full Text](#)
 67. Scherwitz I, Mongkolsapaja J, Screaton G: Recent advances in human flavivirus vaccines. *Curr Opin Virol*. 2017; 23: 95–101.
[PubMed Abstract](#) | [Publisher Full Text](#)
 68. Islam Z, Gilbert M, Mohammad QD, *et al.*: Guillain-Barré syndrome-related *Campylobacter jejuni* in Bangladesh: ganglioside mimicry and cross-reactive antibodies. *PLoS One*. 2012; 7(8): e43976.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status:

Editorial Note on the Review Process

Faculty Reviews are review articles written by the prestigious Members of **Faculty Opinions**. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.

The reviewers who approved this article are:

Version 1

1. **Pei-Yong Shi**
University of Texas Medical Branch, Galveston, TX, USA
Competing Interests: No competing interests were disclosed.
2. **Mehul Suthar**
Emory University, Atlanta, GA, USA
Competing Interests: No competing interests were disclosed.

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research